Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)
Public ClinicalTrials.gov record NCT00977665. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To test the clinical effect of rasagiline on subjects with MSA of the parkinsonian subtype.
Study identification
- NCT ID
- NCT00977665
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 174 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 30 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2009 (Type not available)
- Primary completion
- Oct 2011 (Actual)
- Completion
- Oct 2011 (Actual)
- Last update posted
- Feb 26, 2015
2009 – 2011
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 1004 | Irvine | California | — | — |
| Teva Investigational Site 1014 | La Jolla | California | — | — |
| Teva Investigational Site 1006 | Sunnyvale | California | — | — |
| Teva Investigational Site 1010 | Washington D.C. | District of Columbia | — | — |
| Teva Investigational Site 1061 | Boca Raton | Florida | — | — |
| Teva Investigational Site 1012 | Tampa | Florida | — | — |
| Teva Investigational Site 1009 | Worcester | Massachusetts | — | — |
| Teva Investigational Site 1003 | Ann Arbor | Michigan | — | — |
| Teva Investigational Site 1007 | Rochester | Minnesota | — | — |
| Teva Investigational Site 1011 | St Louis | Missouri | — | — |
| Teva Investigational Site 1008 | Rochester | New York | — | — |
| Teva Investigational Site 1001 | Cleveland | Ohio | — | — |
| Teva Investigational Site 1002 | Philadelphia | Pennsylvania | — | — |
| Teva Investigational Site 1013 | Nashville | Tennessee | — | — |
| Teva Investigational Site 1005 | Houston | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 32 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00977665, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 26, 2015 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00977665 live on ClinicalTrials.gov.